Updates are available Correction dated 2023-11-16

Article History

Received: 5 January 2023

Accepted: 21 April 2023

First Online: 22 May 2023

Change Date: 16 November 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s40337-023-00926-5

Declarations

:

: The research conformed to the International Conference of Harmonization and Good Clinical Practice guidelines and was approved by Health Canada and the Nova Scotia Health Research Ethics Board (File no. 1023099). All participants provided written informed consent for participation.

: Not applicable.

: ARK has been a member of scientific advisory boards, participated in speaker events and received educational grant support from Takeda Inc. and Otsuka/Lundbeck. AK has been a member of scientific advisory boards and participated in speaker events from Takeda Inc. SLM has been a consultant to, or member of, the scientific advisory board of Avanir, Bracket, F. Hoffmann-La Roche Ltd., Idorsia, Mitsubishi Tanabe Pharma Corporation, Myriad, Naurex, Novo Nordisk, Otsuka, Shire, Sunovion, and Takeda (Shire); has been a principal or co-investigator on studies sponsored by Alkermes, Allergan, Avanir, Azevan, Forest, Marriott Foundation, Medibio, Myriad, National Institute of Mental Health, Naurex, Neurocrine, Novo Nordisk, Shire, Sunovion, and Takeda Pharmaceutical Company Limited; and is an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent.